Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$157.06 USD

157.06
759,238

-3.92 (-2.44%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $157.90 +0.84 (0.53%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

PBYI vs. RGEN: Which Stock Is the Better Value Option?

PBYI vs. RGEN: Which Stock Is the Better Value Option?

Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y

Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.

Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of -2.94% and 0.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

HRMY vs. RGEN: Which Stock Is the Better Value Option?

HRMY vs. RGEN: Which Stock Is the Better Value Option?

Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members

Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.

Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat

Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.

Company News for Nov 01, 2023

Companies In The Article Are: AMGN, NVDA, RGEN, COCO

Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 64.29% and 2.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) to Acquire Fluid Management Company Metenova

Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.

Moderna (MRNA) Surges 3.2%: Is This an Indication of Further Gains?

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

Smart Beta ETF report for JSMD

Why Is Repligen (RGEN) Up 2.9% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance

Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.

Repligen (RGEN) Q2 Earnings Surpass Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 8.16% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Repligen (RGEN) Q2 Earnings Expected to Decline

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EXEL or RGEN: Which Is the Better Value Stock Right Now?

EXEL vs. RGEN: Which Stock Is the Better Value Option?

Are Options Traders Betting on a Big Move in Repligen (RGEN) Stock?

Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

Smart Beta ETF report for JSMD